2,073 results on '"Tammela, Teuvo"'
Search Results
2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.
3. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study
4. Allopurinol and prostate cancer survival in a Finnish population-based cohort
5. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
6. Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
7. Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
8. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer
9. The effect of sample size on polygenic hazard models for prostate cancer
10. A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data
11. A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases
12. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
13. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
14. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer
15. The expanded prostate cancer index composite short form (EPIC-26) for measuring health-related quality of life: content analysis of patients’ spontaneous comments written in survey margins
16. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
17. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients
18. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
19. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
20. Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer
21. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
22. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
23. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
24. Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
25. Androgen deprivation therapy-resistant club cells are linked to myeloid cell-driven immunosuppression in the prostate tumor microenvironment
26. Do LUTS Predict Mortality? An Analysis Using Random Forest Algorithms
27. Early detection of clinically significant prostate cancer: protocol summary and statistical analysis plan for the ProScreen randomised trial
28. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
29. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
30. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
31. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study
32. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11
33. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
34. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
35. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
36. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
37. Prostate cancer-related sexual dysfunction – the significance of social relations in men's reconstructions of masculinity.
38. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
39. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.
40. Screening history and risk of death from prostate cancer: a nested case–control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)
41. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men
42. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
43. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs
44. Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
45. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
46. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres
47. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs
48. Overdiagnosis and Overtreatment of Prostate Cancer
49. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
50. Prostate cancer-related sexual dysfunction – the significance of social relations in men’s reconstructions of masculinity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.